Fasenra (Benralizumab) for Asthma | MyAsthmaTeam

Connect with others who understand.

sign up Log in
About MyAsthmaTeam
Powered By

Fasenra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat severe asthma in adults and children 12 years of age and older. Fasenra is also referred to by its drug name, benralizumab.

Fasenra is a member of a class of drugs called monoclonal antibodies. Fasenra is believed to work by binding to a proinflammatory cytokine (chemical messenger) known as interleukin-5 (IL-5) receptor. This binding prevents the maturation of eosinophils, which are white blood cells that release leukotrienes. Leukotrienes are chemicals involved in airway edema (swelling), smooth muscle contraction, and other processes associated with the symptoms of asthma. Inhibiting their release helps to relieve these symptoms.

How do I take it?
Prescribing information states that Fasenra is given as a subcutaneous (under your skin) injection. Fasenra is usually given in a health clinic or doctor’s office once every four weeks for the first three doses and once every eight weeks thereafter. It should be administered according to the frequency specified by the physician.

Fasenra is available only as a subcutaneous injection.

Side effects
The FDA-approved label for Fasenra lists common side effects including headache and sore throat.

Rare but serious side effects listed for Fasenra include severe allergic reactions and parasitic infections.

For more details about this treatment, visit:

Fasenra — AstraZeneca

Benralizumab — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in